Table 2.
Overall survival | |||||||||
---|---|---|---|---|---|---|---|---|---|
Unadjusted model Overall cohort |
Large adjusted model Overall cohort |
Simple adjusted model Overall cohort |
|||||||
HR | 95% CI | p | HR | 95% CI | p | HR | 95% CI | p | |
MCT1 | 1.622 | 1.030–2.554 | 0.037 | 2.123 | 1.145–3.937 | 0.017 | 1.963 | 1.199–3.214 | 0.007 |
Grade | 4.684 | 1.715–12.79 | 0.003 | 3.210 | 1.136–9.076 | 0.028 | 3.797 | 1.372–10.50 | 0.010 |
Stage | 2.288 | 1.500–3.489 | <0.001 | 1.965 | 1.078–3.579 | 0.027 | 2.080 | 1.300–3.328 | 0.002 |
Size | 1.269 | 0.585–2.750 | 0.547 | 0.681 | 0.306–1.515 | 0.346 | – | – | – |
LVSI | 2.347 | 0.935–5.891 | 0.069 | 1.185 | 0.378–3.718 | 0.771 | – | – | – |
MI | 1.447 | 0.609–3.436 | 0.403 | 1.121 | 0.340–3.690 | 0.851 | – | – | – |
Grade categorised as Grade I/II and III tumours; Stage: FIGO 2009 stage categorised as 1, 2, 3 and 4; Size categorised as <2 cm, between 2 and 5 cm and bigger than 5 cm; LVSI: Lymphovascular space involvement categorised as “Yes” and “No”; MI: Depth of myometrial invasion categorised as <50% and more than 50%; HR: hazard ratio, CI: confidence interval. Bold text indicates statistically significant data at p < 0.05 level